In the evolving landscape of medicinal chemistry and drug discovery, the precise synthesis of receptor-specific molecules is a cornerstone of innovation. One of the more intriguing recent developments is the creation of Synthetic EP4 Beta (EP4β) via a carbon link strategy. This compound represents a significant step forward in studying the EP4 receptor, a subtype of the prostaglandin E2 (PGE2) receptor family.
For the medicinal chemist or cell biologist frustrated by the instability of natural prostanoids, the synthetic EP4 beta by carbon link offers a solution. It combines the high-affinity activation of the EP4 receptor with the rugged stability of a synthetic hydrocarbon backbone.
Whether you are investigating bone loss, cancer immunity, or intestinal homeostasis, switching to this carbon-linked analogue ensures that your results reflect the biology of EP4—not the chemistry of degradation. the synthetic ep 4 beta by carbon link
The EP4 receptor is one of four known receptors (EP1-EP4) for the endogenous lipid mediator Prostaglandin E2. It is a G-protein-coupled receptor (GPCR) primarily coupled to the Gs protein, leading to increased intracellular cyclic AMP (cAMP). EP4 plays critical roles in:
Studying EP4 has been challenging due to the existence of multiple EP receptor subtypes with overlapping ligand specificities. Natural PGE2 binds to all four EP receptors with high affinity, making it difficult to isolate EP4-specific effects. Synthetic EP4 Beta by Carbon Link: A New
| Feature | Natural PGE2 | Synthetic EP4 Beta (Carbon Link) | |---------|--------------|----------------------------------| | C-9 hydroxyl | Alpha | Beta | | C-1 linkage | Carboxylic acid (O-link in esters) | Direct carbon-carbon link | | Metabolic half-life | Minutes | Hours | | EP4 selectivity | Low (cross-reacts with EP2/EP3) | High |
Synthetic EP4β by Carbon Link is not yet a marketed drug but is a powerful research tool. Current and potential applications include: Studying EP4 has been challenging due to the
EP4 agonists maintain ductal patency in neonates with ductus-dependent congenital heart disease. The enhanced metabolic stability of the carbon link analog could reduce dosing frequency from every 2 hours to once daily—a significant clinical advantage.
Instead of attaching an omega side chain via an ester or amide bond, a palladium-catalyzed cross-coupling reaction (e.g., Suzuki-Miyaura or Negishi coupling) is employed. A vinyl iodide or triflate intermediate is coupled with an organozinc or organoboron reagent bearing the omega chain. This step directly forges a C-C bond, creating the eponymous carbon link.
| Action | Contact / Method |
|--------|------------------|
| Request a quote for re-synthesis | Email Carbon Link’s custom synthesis team: info@carbonlink.com (verify current contact via their website). Provide the original PO or internal code “EP4 Beta.” |
| Request Certificate of Analysis (CoA) | If previously synthesized, Carbon Link retains batch records. Provide batch number or synthesis date. |
| Design a similar EP4-linker conjugate | Use Carbon Link’s linker selection guide (PEG2-PEG24, alkane, disulfide, or cleavable). Specify “EP4 antagonist derivative with beta-alanine spacer.” |